Metabolisches Syndrom und Krebsrisiko

Krebs zählt zu den führenden Todesursachen beim metabolischen Syndrom (MetS). Je mehr Komponenten des metabolischen Syndroms jemand hat, desto stärker steigt das Tumorrisiko, z. B. Karzinome des Dickdarms. Bei adipösen MetS-Patienten kann die Gewichtsreduktion das Krebsrisiko senken. Dem MetS vorzubeugen und regelmäßig an Vorsorgeuntersuchungen teilzunehmen ist wichtig und verringert das Risiko, an Krebs zu erkranken und daran zu versterben.

Abstract

Cancer has become a leading cause of death among patients with metabolic syndrome (MetS). The more components of MetS a patient has, the higher his risk of cancer. MetS is causally associated with colorectal, pancreatic, gallbladder, biliary, hepatocellular, gastric, esophageal, thyroid, breast, endometrial and renal cell cancers. MetS increases cancer mortality up to 2,4-fold. Intentional long-term weight loss reduces the excess cancer risk of obese MetS-patients. Both a low-risk lifestyle and cancer screening are effective and decrease the burden of cancer.

Schlüsselworter

metabolisches Syndrom - MetS - Tumorrisiko - Prävention - Diabetes - Übergewicht - HDL

Key words

metabolic syndrome - tumor risk - prevention - diabetes - obesity - HDL

Publikationsverlauf

Artikel online veröffentlicht:
15. August 2022

• Literatur

• 1 Dagenais GR, Leong DP, Rangarajan S. et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2020; 395: 785-794
• 2 Lee JS, Cho SI, Park HS. Metabolic syndrome and cancer-related mortality among Korean men and women. Ann Oncol 2010; 21: 640-645
• 3 Gathirua-Mwangi WG, Monahan PO, Murage MJ. et al. Metabolic syndrome and total cancer mortality in the Third National Health and Nutrition Examination Survey. Cancer Causes Control 2017; 28: 127-136
• 4 Watanabe J, Kakehi E, Kotani K. et al. Metabolic syndrome is a risk factor for cancer mortality in the general Japanese population: the Jichi Medical School Cohort Study. Diabetol Metab Syndr 2019; 11: 3
• 5 López-Jiménez T, Duarte-Salles T, Plana-Ripoll O. et al. Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study. PLoS One 2022; 17 (03) e0264634
• 6 Esposito K, Chiodini P, Colao A. et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012; 35: 2402-2411
• 7 Tran TT, Gunathilake M, Lee J. et al. Association between metabolic syndrome and its components and incident colorectal cancer in a prospective cohort study. Cancer 2022; 128: 1230-1241
• 8 Simon TG, King LY, Chong DQ. et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology 2018; 67: 1797-1806
• 9 Sung H, Siegel RL, Rosenberg PS. et al. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health 2019; 4: e137-e147
• 10 Célind J, Bygdell M, Martikainen J. et al. Childhood overweight and risk of obesity-related adult cancer in men. Cancer Commun (Lond) 2022;
• 11 Ulmer H, Borena W, Rapp K. et al Serum triglyceride concentrations and cancer risk in a lare cohort study in Austria. Br J Cancer 2009; 101: 1202-1206
• 12 Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 2010; 55: 2846-2854
• 13 Stocks T, Van Hemelrijck M, Manjer J. et al Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension 2012; 59: 802-810
• 14 Moore SC, Lee IM, Weiderpass E. et al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Intern Med 2016; 176: 816-825
• 15 Papadimitriou N, Markozannes G, Kanellopoulou A. et al. An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites. Nat Commun 2021; 12: 4579
• 16 Rustgi VK, Li Y, Gupta K. et al. Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. Gastroenterology 2021; 161 (01) 171-184
• 17 Sjöholm K, Carlsson LMS, Svensson PA. et al. Association of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-Term Results From the Swedish Obese Subjects Study. Diabetes Care 2021; 45 (02) 444-450
• 18 Wang L, Lin M, Yu J. et al. The Impact of Bariatric Surgery Versus Non-Surgical Treatment on Blood Pressure: Systematic Review and Meta-Analysis. Obes Surg 2021; 31: 4970-4984
• 19 Syn NL, Cummings DE, Wang LZ. et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet 2021; 397: 1830-1841
• 20 Vuik F, Nieuwenburg S, Bardou M. et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 2019; 68: 1820-1826
• 21 Shen X, Wang Y, Zhao R. et al. Metabolic syndrome and the risk of colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 2021; 36: 2215-2225
• 22 O’Sullivan DE, Sutherland RL, Town S. et al. Risk Factors for Early-Onset Colorectal Cancer: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021; 20 (06) 1229-1240
• 23 Milano A, Bianco MA, Buri L. et al. Metabolic syndrome is a risk factor for colorectal adenoma and cancer: a study in a White population using the harmonized criteria. Therap Adv Gastroenterol 2019; 12
• 24 Lu L, Koo S, McPherson S. et al. Systematic review and meta-analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes. Colorectal Dis 2022;
• 25 Davidson KW, Barry MJ, Mangione CM. US Preventive Services Task Force. et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 325: 1965-1977
• 26 Chen Y, Li X, Wu S. et al. Metabolic syndrome and the incidence of hepatocellular carcinoma: a meta-analysis of cohort studies. Onco Targets Ther 2018; 11: 6277-6285
• 27 McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology 2021; 73 (Suppl. 01) 4-13
• 28 Hajifathalian K, Tafesh Z, Rosenblatt R. et al. Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease: A Prospective United States Cohort Study. J Clin Gastroenterol 2022; 56: 173-180
• 29 Cunha V, Cotrim HP, Rocha R. et al. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. Ann Hepatol 2020; 19: 232-237
• 30 Chen CL, Yang HI, Yang WS. et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-121
• 31 Ghidini M, Ramai D, Facciorusso A. et al. Metabolic disorders and the risk of cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021; 15: 999-1007
• 32 Hwang KT, Han KD, Oh S. et al. Influence of Metabolic Syndrome on Risk of Breast Cancer: A Study Analyzing Nationwide Data from Korean National Health Insurance Service. Cancer Epidemiol Biomarkers Prev 2020; 29: 2038-2047
• 33 Penaranda EK, Shokar N, Ortiz M. Relationship between Metabolic Syndrome and History of Cervical Cancer among a US National Population. ISRN Oncol 2013; 2013: 840964
• 34 Zhang H, Kong W, Han C. et al. Correlation of Metabolic Factors with Endometrial Atypical Hyperplasia and Endometrial Cancer: Development and Assessment of a New Predictive Nomogram. Cancer Manag Res 2021; 13: 7937-7949
• 35 Wang L, Du ZH, Qiao JM. et al. Association between metabolic syndrome and endometrial cancer risk: a systematic review and meta-analysis of observational studies. Aging (Albany NY) 2020; 12 (10) 9825-9839
• 36 Zhang Q, Chen P, Tian R. et al. Metabolic Syndrome is an Independent Risk Factor for Fuhrman Grade and TNM Stage of Renal Clear Cell Carcinoma. Int J Gen Med 2022; 15: 143-150
• 37 Park JH, Han K, Hong JY. et al. Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study. Gastroenterology 2022; 162: 509-520
• 38 Kartal E, Schmidt TSB, Molina-Montes E. et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut 2022; 71 (07) 1359-1372
• 39 Santos AP, Santos AC, Castro C. et al. Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Cancers (Basel) 2018; 10 (09) 293
• 40 Zhang J, Wu H, Wang R. Metabolic syndrome and esophageal cancer risk: a systematic review and meta analysis. Diabetol Metab Syndr 2021; 13 (01) 8
• 41 Mariani M, Sassano M, Boccia S. Metabolic syndrome and gastric cancer risk: a systematic review and meta-analysis. Eur J Cancer Prev 2021; 30 (03) 239-250
• 42 Jun JK, Choi KS, Lee HY. et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology 2017; 152: 1319-1328
• 43 Zhou CB, Pan SY, Jin P. et al. Fecal Signatures of Streptococcus anginosus and Streptococcus constellatus for Noninvasive Screening and Early Warning of Gastric Cancer. Gastroenterology 2022; 162 (07) 1933-1947